Berkeley, CA, United States
Berkeley, CA, United States

Time filter

Source Type

News Article | April 21, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "European Procedure Numbers for Gynecological Devices 2016 - MedPro" report to their offering. In the case of Uterine Fibroid Embolization, the number of patients receiving treatments also demonstrates the number of procedures being performed using Microspheres compared to PVA particles. The changes in Essure® procedures provides a context for the adverse health effects currently being publicized and the impact it is having on potential patients. Finally, for both Female Urinary Incontinence Sling procedures and Pelvic Organ Prolapse procedures, there is a 1:1 ratio between unit sales and the number of procedures performed. However, the procedure numbers illustrate doctor and patient preferences as there is a shift in the types of slings and meshes used for procedures. The procedures included in this segment all link to the unit sales for capital equipment. The Assisted Reproduction device market demonstrates the relationship between the average number and types of supplies used per cycle of IVF or ICSI. The procedural data also helps to clarify the unit sales in the different sub-segments of the gynecology market. For more information about this report visit http://www.researchandmarkets.com/research/l9qhqc/european


News Article | April 25, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "European Market Report for Assisted Reproduction Devices 2016 - MedCore" report to their offering. Procedures in the assisted reproduction market are projected to experience strong but stable growth throughout the forecast period. Unlike other industries within gynecology, the assisted reproduction market is minimally affected by economic downturns. This is potentially because unlike costly procedures that are able to be delayed, the age of females significantly impacts fertility and the success rate of becoming pregnant. The largest changes in the market are in terms of emerging technology and superior processes to perform assisted reproduction treatments. As more research is published, the industry is adapting to optimize success rates. Patient reimbursement and differing legislation by country also produces a substantial impact on procedure numbers across Europe. Assisted reproduction technologies (ART) help women or couples conceive children. Most couples who use ART are affected by infertility, although ART can also be used to help lesbian couples or single women. A couple is considered to be infertile if they have not conceived after one year of intercourse without birth control. While there are a number of techniques used to aid fertilization, the products discussed in this chapter are those used for in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). An IVF procedure removes the woman's eggs and then fertilizes them with sperm in a lab setting. IVF has been very successful in helping couples become pregnant within their first or second cycle. ICSI takes a sperm cell and injects it directly into an egg. ICSI can facilitate fertilization in conjunction with IVF. For more information about this report visit http://www.researchandmarkets.com/research/l3zjtr/european_market


News Article | October 28, 2016
Site: www.prweb.com

Shady Grove Fertility, a leader in reproductive medicine and clinical research, published a new study that identifies a promising new method for selecting functionally viable sperm, which shows promise for improving fertilization and embryo development for patients who need assisted reproductive technologies (ART). For decades, male factor infertility was the most difficult form of infertility to successfully treat and overcome. That all changed in 1992 with the introduction of intracytoplasmic sperm injection (ICSI). While this breakthrough was able to successfully treat most cases of male factor infertility, there remain couples for whom poor sperm quality remains a barrier to treatment success. This year at the American Society of Reproductive Medicine’s 2016 Scientific Congress and Expo in Salt Lake City, October 15 to 19, Shady Grove Fertility scientist, Matteo Avella, Ph.D., presented a study that identifies a new sperm selection assay that helps select the best sperm—those with a greater ability to bind and penetrate eggs—in the hopes of improving outcomes for these patients (Poster Number#: P–16, Sci. Transl. Med. 335: 336ra60, 2016). This method, which has recently been highlighted in top-ranking scientific journals (Nature; Nature Reviews Urology; Science News) as well as by the international media (Daily Mail; Telegraph) could prove useful in selecting the most viable sperm for intracytoplasmic sperm injection (ICSI). In vitro fertilization (IVF) is achieved in one of two ways: conventional insemination or intracytoplasmic sperm injection (ICSI). For conventional insemination, the embryologist simply combines eggs and semen in a dish, giving the sperm the opportunity to penetrate and fertilize the eggs. With ICSI, instead of mixing thousands of sperm with the eggs, the embryologist selects a single sperm and injects it directly into each egg. The next day, each egg is checked for evidence of fertilization. While ICSI has dramatically improved treatment success rates in couples with severe male factor infertility, improved sperm selection holds potential to yield even better outcomes by improving chances of fertilization and development of the resulting embryos. In this study, researchers generated special microscopic beads that mimic human eggs. These beads are coated of a protein called ZP2. In humans, ZP2 is found in the zona pellucida, the egg envelope that surrounds eggs. Sperm must bind specifically to this protein in order to fertilize the egg. These ZP2-coated beads/mock eggs can attract ‘the best’ sperm and will be used for patients requiring ICSI. Given this research study identified a promising new method for selecting functionally viable sperm with superior ability to bind and penetrate the outer coating of the egg, use of sperm selected by this method may improve fertilization and embryo development for patients who need assisted reproductive technologies (ART). Researchers at Shady Grove Fertility are currently planning a larger randomized controlled trial to further evaluate the ability of this innovative technology to help patients. This study is one of many examples of how Shady Grove Fertility’s researchers and physicians strive to give patients access to the most up-to-date and effective treatment options. About the 2016 ASRM Scientific Congress & Expo The 2016 ASRM Scientific Congress & Expo is the premier scientific congress for reproductive medicine that will address state-of-the-art issues in reproductive medicine and science. Held from October 15 to 19, 2016, in Salt Lake City, UT, the theme of the 2016 Scientific Congress of the American Society for Reproductive Medicine is “Scaling New Heights in Reproductive Medicine.” The program features scientific, postgraduate, and video presentations as well as plenary lectures addressing the most pressing clinical and basic-science issues in reproductive medicine. About Shady Grove Fertility Shady Grove Fertility is a leading fertility and IVF center of excellence offering patients individualized care, innovative financial options, and pregnancy rates among the highest of all national centers. 2016 commemorates 25 years of Shady Grove Fertility providing medical and service excellence to patients from all 50 states and 35 countries around the world, and celebrates over 40,000 babies born—more than any other center in the nation. Today, 34 reproductive endocrinologists, supported by a highly specialized team of 600 urologists, Ph.D. scientists, geneticists, and staff care for patients in 19 full-service offices and six satellite sites throughout Maryland, Pennsylvania, Virginia, and Washington, D.C. Shady Grove Fertility physicians actively train residents and reproductive endocrinology fellows and invest in continuous clinical research and education to advance the field of reproductive medicine through numerous academic appointments and partnerships such as Georgetown Medical School, Walter Reed National Military Medical Center, the University of Maryland, and the National Institutes of Health. More than 1,700 physicians refer their patients to Shady Grove Fertility each year. For more information, call 1-888-761-1967 or visit https://www.shadygrovefertility.com.


News Article | February 15, 2017
Site: www.prweb.com

Pacific Reproductive Center's live birth success rates are now exceeding the national average by fifteen percent. This includes success rates for women who are undergoing egg retrievals and IVF procedures. Call (310) 853-5793 for more information and scheduling. For over twenty years, Pacific Reproductive Center and Dr. Rifaat Salem have been compassionately helping women with infertility issues achieve their fertility goals. This includes comprehensive options for therapy, such as ovulation induction, ICSI, IVF, IUI and more. Over the years, PRC has been instrumental in pioneering state-of-the-art reproductive technologies. This includes preimplantation genetic testing, in-house IVF and ICSI as well. The success rate of 57% for those under 35 years old is exceptionally high compared to the national average, and has helped thousands of women achieve their fertility goals over the past two decades. PRC has four locations in the LA and OC metro areas including Glendale, Torrance, Irvine and Corona CA. Treatment is provided with Board Certified providers who are caring and work to individualize the treatments based on a patient's previous experiences. For those between the ages of 38-40, PRC still maintains success rates over ten percent higher than the national average. For top fertility treatment in Los Angeles and Orange County, visit http://pacificreproductivecenter.com and then call Pacific Reproductive Center at (310) 853-5793.


LONDON--(BUSINESS WIRE)--Technavio’s latest market research report on the global assisted reproductive technology (ART) market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline. Amber Chourasia, a lead analyst from Technavio, specializing in research on health and wellness sector says, “Assisted reproductive technology is a wide range of procedures that are used to treat infertility in men and women. Generally, ART procedures include techniques, such as IVF, ZIFT, GIFT, ICSI, and artificial insemination, which help individuals to conceive a child. The assisted fertility market is expected to witness consistent growth during the forecast period owing to an increase in infertility treatment.” Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. The top three emerging market trends driving the global assisted reproductive technology market according to Technavio research analysts are: Women are delaying pregnancy because of various factors, leading to an increase in the rate of pregnancies in older women. Factors such as economic pressure, interest in career, and changes in relationships have led to the postponing of marriage and children. Another impacting factor is the increased use of contraceptives due to the rise in government investment in sex education programs, resulting in teens using long-acting forms of birth control. This development has stalled birth rates among women in their 20s, but increased birth rates among those aged between 30 and 44 years. “Thus, with increasing age, the chances of conception reduce due to a drop in fertility, which stimulates the need for repeated testing and dependence on assisted reproductive technologies,” says Amber. Innovation and effectiveness of ART procedures such as in vitro fertilization (IVF) are the keys to the growth of the market. Several vendors are entering strategic alliances and investing in R&D for innovation and improvement of existing ART technologies. Strategic alliances have resulted in better financial stability to develop the latest products with enhanced efficiency, in terms of safety and protection. M&As allow vendors to gain access to proprietary technologies and advanced products of the acquired company. Some small vendors undergo M&As to broaden their network and expand the penetration of their new products. Some companies and government organizations form collaborations to conduct R&D of fertility technologies. These collaborations allow both companies to use their proprietary technologies to develop innovative products. This trend of mergers and acquisitions allows for the development of better products and services thus, leading to the higher growth potential of the market during the forecast period. Increase in acceptance of same sex marriages Social and legal acceptance of same sex marriages has also led to a rise in sperm donations and the use of fertility services. According to a research by the Williams Institute, in the US, an estimated six million children in the country had same sex couples as parents. The use of donor sperm by same sex female couples increased from 15% before the legalization of same sex marriages to 20% after the legalization of the same. The invalidation of the ‘Defense of Marriage Act’ in 2013 has led to an increased demand for fertility services in the US, which in turn, increases the demand for ART. Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like home, kitchen and large appliances, lab equipment, and outdoor gear. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at media@technavio.com.


News Article | October 26, 2016
Site: www.newscientist.com

A small study of men who were conceived in the 1990s using a now common fertility treatment suggests that they are themselves less fertile. Intra-cytoplasmic sperm injection (ICSI) is a technique that injects sperm directly into an egg to fertilise it. This method is commonly used to overcome various types of male infertility – including low sperm count, abnormal sperm, or sperm that doesn’t move well – and was used in about half of IVF treatments using non-frozen embryos in the UK in 2013. Because the method can allow non-motile sperm to create an embryo, scientists have suspected that it can pass genetic causes of infertility to the next generation. Now there is some evidence that this could be the case. Comparing 54 men who were conceived using ICSI with 57 men whose parents conceived naturally, Andre Van Steirteghem at the Vrije Universiteit Brussel in Belgium and his colleagues have found that the ICSI men had almost half the sperm concentration of the control group, and a two-fold lower count of motile sperm. “These findings are not unexpected,” says Steirteghem. “Before ICSI was carried out, prospective parents were informed that it may well be that their sons may have impaired sperm like their fathers.” These parents still decided to try the technique, thinking that their sons could themselves use ICSI if necessary, he says. The ICSI men were all born between 1992 and 1996, during the early years of the technique. On average, they were almost three times more likely to have sperm concentrations below the World Health Organization’s definition of normal. “Whilst these young men may have lower sperm counts than the general population, they may still be able to father children without treatment,” says Adam Balen, of the British Fertility Society. Steirteghem stresses that these results show a correlation, not a causal link. While genetics plays a role in male infertility, other factors may also interfere, he says. Allan Pacey, at the University of Sheffield, notes that the sperm quality of the fathers in the study didn’t always match that of their sons. “It doesn’t automatically follow that ICSI-conceived males will always have the poor fertility seen by their fathers,” he says. Read more: We took his-and-hers fertility tests – this is what it was like


News Article | October 28, 2016
Site: co.newswire.com

TransferMan NK2 From Eppendorf is a product used in IVF Laboratory and is the best micromanipulators for IVF / ICSI procedures. The Eppendorf TransferMan NK2 is used routinely for microinjection of DNA into the pronucleus of zygotes and injection of embryonic stem cells into blastocysts. Operating the TransferMan NK 2 micromanipulator, with its few self-explanatory keys, is extremely simple.


News Article | February 22, 2017
Site: motherboard.vice.com

When Sara Hesse was tagged on Facebook last May for a crowdfunding campaign, she hesitated. The project was asking for $4000 up front, to help build a budget fertility clinic in Calgary, which would offer her one round of a sort of do-it-yourself in vitro fertilization treatment in return for her support. She and her husband, Chad, were already on a waiting list at the Regional Fertility Program, the only other clinic in town, which charges around $16,000 for a round of conventional IVF. (Both prices include drug costs.) The couple, in their early thirties, discussed it for about a week. But just one day after the campaign formally opened, they were in. "First and foremost," said Sara in an interview, "it was cost." The Hesses were number 27 on a list of 100 "founder" patients. The first 19 patients signed up on the very first day, and all 100 were on board within 65 days. The clinic, called Effortless IVF, opened its doors to these initial 100 patients on Feb 14. It plans to open to more patients—some 60 more are now in line—in early March, said Jason Broome, the clinic's co-founder and director. Conventional IVF and this newer variant—called intravaginal culture, or IVC—both involve stimulating the ovaries to produce extra eggs, removing the eggs surgically, putting sperm and eggs together artificially and placing nicely-developed embryos into the uterus. But there are some key differences. The most obvious is where fertilization and early embryo development take place. In classic IVF, that happens outside the body. In IVC, all of that takes place inside a woman's body—specifically, inside a little plastic capsule tucked inside her vagina. The 4cm-by-3cm capsule, called an INVOcell, is about the size and shape of an old photographic film canister. Made of polystyrene (just like petri dishes), it is gas-permeable, so appropriate levels of carbon dioxide and oxygen can be maintained inside it by the woman's own body. She also keeps the temperature even and filters out toxins with her liver and kidneys. These are complex and expensive operations when handled by a mechanical incubator, but "effortless" when managed in-house, according to Broome. Under this new protocol, eggs will spend only five minutes co-incubating with sperm outside the body, before being placed into the capsule, with a scrum of sperm hanging onto their outer shells. The INVOcell capsule will remain inside the woman's body, held in place by a diaphragm-like retention device, for five days, during which time winning sperm will declare themselves and embryonic development will kick off. On day five, the capsule is removed, the best one or two embryos are selected for transfer into the uterus, and any remaining good embryos are frozen for future use. The INVOcell, owned by INVO Bioscience in Medford Massachusetts, was approved by Health Canada in 2014 and by the FDA a year later. Not having to pay for 24-hour incubators and all the sensors needed to make sure they are functioning properly accounts for a part of the budget price—which, for post-founder patients, is $6500, plus an administrative fee. But other details about how the clinic will work are different too. Effortless IVF patients, for instance, will not be intensely monitored as they take drugs to promote egg production. Normally, women go for blood tests and ultrasounds every few days, but in this new model, doctors prescribe very low doses of the drugs, based on body weight and a measure of egg volume, and then they schedule a single ultrasound on day 10. Using a lower dose of fertility drugs not only lowers the actual drug costs; it also reduces the risk of complications, and therefore the need for extensive monitoring, said Broome. Other protocols make it possible for the clinic to close on weekends—which also saves money. For instance, all day 10 ultrasounds will happen on a Monday, said Broome, and based on how the eggs are developing on that day, the egg retrieval will be scheduled for either Wednesday, Thursday or Friday that same week. The INVOcell will remain in place for five days after that, meaning that embryos are transferred to the uterus on either a Monday, a Tuesday or a Wednesday the following week. Read More: An Egg Freezing 'Pop-Up Store' Appears in London The clinic places a premium on accessible communications, with payments, appointment bookings, reminders and medical records available online. Broome called it "digital healthcare"—something not common in Canadian fertility medicine. For all the differences, though, ultimate success rates appear to be about the same. Broome, along with Kevin Doody and Kathleen Doody, who are fertility doctors at the Center for Assisted Reproduction in Bedford, Texas, randomly assigned 40 women to receive either IVF or IVC, and placed up to 10 eggs into either an INVOcell or an incubator. Rates of fertilization, pregnancy and live birth were all similar between the groups, they reported last April in the Journal of Assisted Reproduction and Genetics, although classic IVF produced more high-quality embryos. There were 11 successful pregnancies in the IVC group and 12 in the IVF group. The process won't work for everyone. Couples who need intracytoplasmic sperm injection (ICSI) for problem sperm, for instance, won't benefit. Women at risk of overstimulating, such as those with polycystic ovaries, may not want to do their cycles without careful monitoring. Obese women may not fit the bill either. And anyone looking to do genetic testing on their embryos won't get that through this budget clinic. The Calgary clinic—which is a walk-in, with no referral necessary—is the first stand-alone IVC clinic in the world, said Broome. He has plans to bring something similar to Montreal, Toronto and Vancouver. Get six of our favorite Motherboard stories every day by signing up for our newsletter.


Grant
Agency: Department of Defense | Branch: Defense Threat Reduction Agency | Program: STTR | Phase: Phase I | Award Amount: 150.00K | Year: 2015

With missions surrounding counterproliferation, nonproliferation and WMD reduction, the stakes for DTRA are incredibly high. Effectively conducting this work involves cooperation and coordination across a wide range of military and government organizations throughout the United States and the world. The decentralization of threats has led to an explosion in the sources and types of data needed to identify, track, and mitigate these threats. Managing highly diverse information drawn from a wide range of agencies and open sources is exceptionally challenging. Even when this problem is restricted to unstructured text, there is simply too much data coming from too many sources for any analyst to appropriately handle all available information and effectively exploit the knowledge it contains with current NLP technologies. Under the Semantic Parsing and role Labeling In Combination Effort (SPLICE), DAC has partnered with the ICSI to build a Deep NLP capability that combines the strengths of Semantic Parsing with those of Semantic Role Labeling. The resulting Deep NLP capability will: 1) find links between entities, events and concepts that previously could only be found through manual analysis; and 2) support population of semantically structured knowledge bases with the confidence that all relevant available information can be fully exploited.


Grant
Agency: Department of Defense | Branch: Air Force | Program: STTR | Phase: Phase I | Award Amount: 150.00K | Year: 2014

ABSTRACT: Although Natural Language Processing research has produced powerful techniques for parsing and data extraction, computers remain mostly oblivious to the meaning of the language they process. Computers cannot, in general, connect the words and phrases in language to a larger model of the world that permits reasoning about the implications of what is written or said. We propose an algorithm that analyzes text-based language data using a method of inference designed to match the way humans process and describe activities and events. Our approach to language understanding combines text with external knowledge encoded in a flexible and expressive structure called an X-net. X-nets, invented by DAC team member Dr. Srinivas Narayanan, act as abstract and computationally efficient simulation of activities, states, and events. Unlike other inference techniques, X-nets make it practical to perform inference on language describing complex, uncertain, and interrelated events that unfold over time. We will evaluate our text inference capability using the same evaluation measures used to assess reading comprehension in middle and high school. BENEFIT: If we are successful, the technology developed under this effort will represent a major step towards the development of algorithms that achieve human-like understanding of text. Computers will be able to find and react to language data based on its meaning and implications, rather than the surface form of the words used. Existing stores of language data will become enormously more valuable once we can extract information based on implications instead of key words. And general-purpose, meaning-aware language understanding algorithms will act as the foundation of a new generation of data analysis and human interaction tools. In Phase I of this project, we focus on understanding the language of the limited domain of disasters and disaster response. Humanitarian Aid / Disaster Relief (HADR) is important to many Government, NGO, and private organizations. The results of Phase I of this project will be immediately applicable to a number of our current and potential customers who need exploit text data generated from large-scale, rapidly evolving events such as natural disasters.

Loading ICSI collaborators
Loading ICSI collaborators